BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 29129561)

  • 1. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A 16-Year Australian Single Centre Experience.
    Nogic J; Koh Y; Bak M; Gooley RP; Meredith IT; McCormick LM
    Heart Lung Circ; 2018 Dec; 27(12):1446-1453. PubMed ID: 29129561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies.
    Alam M; Dokainish H; Lakkis N
    J Interv Cardiol; 2006 Aug; 19(4):319-27. PubMed ID: 16881978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term clinical follow-up of patients undergoing percutaneous alcohol septal reduction for symptomatic obstructive hypertrophic cardiomyopathy.
    Fortunato de Cano S; Nicolas Cano M; de Ribamar Costa J; Alves Pinheiro J; Bellio de Mattos Barretto R; Costa de Souza Le Bihan D; Abizaid A; Sousa A; Eduardo Sousa J
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):953-960. PubMed ID: 27143093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and three-year noninvasive follow-up in 18 patients.
    Guo H; Wang J; Chen J; Shan J; Lee JD; Ueda T
    Can J Cardiol; 2004 Jun; 20(8):779-82. PubMed ID: 15229758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients.
    Seggewiss H; Gleichmann U; Faber L; Fassbender D; Schmidt HK; Strick S
    J Am Coll Cardiol; 1998 Feb; 31(2):252-8. PubMed ID: 9462563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alcohol septal ablation in hypertrophic cardiomyopathy utilizing a longitudinal 17-year study (mean 10.8). Observation follow-ups taken at a single medical centre.
    Wojtarowicz A; Kornacewicz-Jach Z
    Cardiol J; 2017; 24(2):125-130. PubMed ID: 27734458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percutaneous alcohol septal ablation for hypertrophic obstructive cardiomyopathy: technical review and long-term clinical and echocardiographic outcomes.
    Leal S; Galeote G; Jiménez-Valero S; Sánchez-Recalde A; Salinas P; Ruiz AS; Orbe LC; Dominguéz F; Moreno R; López-Sendón JL
    Rev Port Cardiol; 2012 May; 31(5):363-71. PubMed ID: 22482474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Outcome After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: An Echocardiography and Cardiovascular Magnetic Resonance Imaging Study.
    Lu M; Du H; Gao Z; Song L; Cheng H; Zhang Y; Yin G; Chen X; Ling J; Jiang Y; Wang H; Li J; Huang J; He Z; Zhao S
    Circ Cardiovasc Interv; 2016 Mar; 9(3):e002675. PubMed ID: 26884612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early remodelling of left ventricle and improvement of myocardial performance in patients after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy.
    Veselka J; Honek T
    Int J Cardiol; 2003 Mar; 88(1):27-32. PubMed ID: 12659981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy.
    Shelke AB; Menon R; Kapadiya A; Yalagudri S; Saggu D; Nair S; Narasimhan C
    Indian Heart J; 2016; 68(5):618-623. PubMed ID: 27773399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender Disparities in Clinical Outcome After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy in the Chinese Han Population: A Cohort Study.
    Wang Y; Zhao HW; Wang CF; Meng QK; Cui CS; Zhang XJ; Zhu Y; Fan CY; Luo DF; Chen BJ; Luan B; Hou AJ
    Heart Lung Circ; 2020 Dec; 29(12):1856-1864. PubMed ID: 32611501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short- and long-term outcome after alcohol septal ablation in obstructive hypertrophic cardiomyopathy: Experience of a reference center.
    Aguiar Rosa S; Fiarresga A; Galrinho A; Cacela D; Ramos R; de Sousa L; Gonçalves A; Bernardes L; Patrício L; Branco LM; Ferreira RC
    Rev Port Cardiol (Engl Ed); 2019 Jul; 38(7):473-480. PubMed ID: 31495717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy; The Chinese experience in 119 patients from a single center.
    Li ZQ; Cheng TO; Zhang WW; Qiao SB; Zhao LY; Jin YZ; Guan RM; Liu L
    Int J Cardiol; 2004 Feb; 93(2-3):197-202. PubMed ID: 14975547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation of immediate decrease in ventricular septal strain after alcohol septal ablation for obstructive hypertrophic cardiomyopathy to long-term reduction in left ventricular outflow tract pressure gradient.
    van Ramshorst J; Mollema SA; Delgado V; van der Wall EE; Schalij MJ; Atsma DE; Bax JJ
    Am J Cardiol; 2009 Jun; 103(11):1592-7. PubMed ID: 19463521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy].
    Qiao SB; Gao RL; You SJ; Yuan JS; Chen JL; Yang YJ
    Zhonghua Nei Ke Za Zhi; 2006 Mar; 45(3):210-2. PubMed ID: 16624154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to significant gradient reduction following septal balloon occlusion predicts the magnitude of final gradient response during alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy.
    Almasood A; Garceau P; Woo A; Rakowski H; Schwartz L; Overgaard CB
    JACC Cardiovasc Interv; 2011 Sep; 4(9):1030-4. PubMed ID: 21939945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy.
    Seggewiss H; Faber L; Gleichmann U
    Thorac Cardiovasc Surg; 1999 Apr; 47(2):94-100. PubMed ID: 10363608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis.
    Alam M; Dokainish H; Lakkis NM
    Eur Heart J; 2009 May; 30(9):1080-7. PubMed ID: 19233857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery.
    Qin JX; Shiota T; Lever HM; Kapadia SR; Sitges M; Rubin DN; Bauer F; Greenberg NL; Agler DA; Drinko JK; Martin M; Tuzcu EM; Smedira NG; Lytle B; Thomas JD
    J Am Coll Cardiol; 2001 Dec; 38(7):1994-2000. PubMed ID: 11738306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percutaneous transluminal septal myocardial ablation in drug-resistant hypertrophic obstructive cardiomyopathy: 18-month follow-up results.
    Oomman A; Ramachandran P; Subramanyan K; Kalarickal MS; Osman MN
    J Invasive Cardiol; 2001 Jul; 13(7):526-30. PubMed ID: 11435640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.